XIANG YANQUN

Quick facts

Phase 3 pipeline

• Capecitabine/Placebo combined with toripalimab · Oncology
  Capecitabine is a prodrug chemotherapy that converts to fluorouracil to inhibit thymidylate synthase, while toripalimab is a PD-1 inhibitor that restores anti-tumor immune responses.
• GP Combined With Camrelizumab · Oncology
  GP (gemcitabine/cisplatin chemotherapy) combined with camrelizumab (a PD-L1 inhibitor) works by killing cancer cells directly while simultaneously unleashing immune responses against tumors.
• GP combined with Tislelizumab · Oncology
  GP combined with Tislelizumab uses a chemotherapy backbone (likely gemcitabine/cisplatin) paired with an anti-PD-1 immunotherapy to kill cancer cells and enhance immune-mediated tumor destruction.
• TPC combined with Tislelizumab · Oncology
  TPC combined with Tislelizumab uses chemotherapy to damage cancer cells while Tislelizumab blocks PD-1 to enhance immune recognition and attack of tumors.

Phase 2 pipeline

• Irinotecan Liposomal combined With Nituzumab

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• XIANG YANQUN portfolio CI brief
• XIANG YANQUN pipeline updates RSS